Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Gary J SchillerPinkal Desai

Abstract

In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become increasingly common in patients with acute myelogenous leukemia (AML) due to improved donor availability and the use of nonmyeloablative regimens. However, despite the potential clinical gains with allo-HSCT, the post-transplantation outcomes for many patients, especially those with high-risk disease, remain dismal. Patients with AML who have internal tandem duplication mutations in the tyrosine kinase receptor FLT3 (FLT3-ITD) face particularly poor outcomes, even after allo-HSCT, which appears to only partially mitigate the poor prognosis associated with this mutation. Experimental treatments to reduce the likelihood of relapse and improve survival following allo-HSCT include maintenance with FLT3-specific tyrosine kinase inhibitors (TKIs), several of which are currently being evaluated in clinical studies. Preliminary data and case reports suggest that FLT3 TKIs can be effective in the post-transplantation setting, particularly for patients with FLT3-ITD mutations. Improvements in donor matching, transplantation procedures, and supportive care have allowed a greater number of patients to undergo allo-HSCT than ever before. For these pat...Continue Reading

References

Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Feb 22, 2007·Blood·Martin BornhäuserUNKNOWN AML SHG 96 study group
Jan 25, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Denise M OlianskyTheresa Hahn
Sep 6, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephen SpellmanCarolyn Katovich Hurley
Jul 9, 2009·Bone Marrow Transplantation·P LjungmanUNKNOWN European Group for Blood and Marrow Transplantation
Feb 10, 2010·Expert Opinion on Investigational Drugs·Munira Shabbir, Robert Stuart
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian L McCluneSergio Giralt
Feb 18, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Amy E DeZernMark Levis
Jul 20, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Manish SharmaMarcos de Lima
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salut BrunetVanderson Rocha
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan J CornelissenBob Löwenberg
Feb 5, 2013·Blood·Marta PratcoronaUNKNOWN Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
Mar 5, 2013·Current Hematologic Malignancy Reports·Raya MawadJohn M Pagel
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Theresa HahnNavneet S Majhail
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hubert ServeWolfgang E Berdel

❮ Previous
Next ❯

Citations

Nov 29, 2016·European Journal of Haematology·Christina RautenbergThomas Schroeder
Nov 23, 2017·Leukemia & Lymphoma·Mrinal M Patnaik
Nov 30, 2019·Journal of Clinical Pharmacy and Therapeutics·Robert ManciniFinn Petersen
May 20, 2020·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Santosh Raut KurmiRahul Bhargava
Jul 28, 2019·Current Hematologic Malignancy Reports·Courtney DiNardo, Curtis Lachowiez
Jul 6, 2019·Journal of Hematology & Oncology·Simona PiemonteseUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Nov 9, 2019·Therapeutic Advances in Hematology·Abdul Hamid BazarbachiAli Bazarbachi
Sep 18, 2018·Leukemia Research·Chetasi Talati, Kendra Sweet
Sep 18, 2021·Current Opinion in Hematology·Anne E Austin, Michael Byrne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.